1. Home
  2. RPRX vs GFS Comparison

RPRX vs GFS Comparison

Compare RPRX & GFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RPRX
  • GFS
  • Stock Information
  • Founded
  • RPRX 1996
  • GFS 2009
  • Country
  • RPRX United States
  • GFS United States
  • Employees
  • RPRX N/A
  • GFS N/A
  • Industry
  • RPRX Biotechnology: Pharmaceutical Preparations
  • GFS Semiconductors
  • Sector
  • RPRX Health Care
  • GFS Technology
  • Exchange
  • RPRX Nasdaq
  • GFS Nasdaq
  • Market Cap
  • RPRX 16.2B
  • GFS 18.5B
  • IPO Year
  • RPRX 2020
  • GFS 2021
  • Fundamental
  • Price
  • RPRX $39.45
  • GFS $33.02
  • Analyst Decision
  • RPRX Strong Buy
  • GFS Buy
  • Analyst Count
  • RPRX 3
  • GFS 10
  • Target Price
  • RPRX $46.00
  • GFS $40.60
  • AVG Volume (30 Days)
  • RPRX 3.9M
  • GFS 3.3M
  • Earning Date
  • RPRX 11-05-2025
  • GFS 11-12-2025
  • Dividend Yield
  • RPRX 2.23%
  • GFS N/A
  • EPS Growth
  • RPRX N/A
  • GFS N/A
  • EPS
  • RPRX 1.75
  • GFS N/A
  • Revenue
  • RPRX $2,349,844,000.00
  • GFS $6,791,000,000.00
  • Revenue This Year
  • RPRX $36.16
  • GFS $1.04
  • Revenue Next Year
  • RPRX $2.04
  • GFS $8.15
  • P/E Ratio
  • RPRX $22.53
  • GFS N/A
  • Revenue Growth
  • RPRX 3.70
  • GFS 0.25
  • 52 Week Low
  • RPRX $24.05
  • GFS $29.77
  • 52 Week High
  • RPRX $41.24
  • GFS $47.69
  • Technical
  • Relative Strength Index (RSI)
  • RPRX 60.31
  • GFS 41.26
  • Support Level
  • RPRX $38.82
  • GFS $32.14
  • Resistance Level
  • RPRX $40.01
  • GFS $33.89
  • Average True Range (ATR)
  • RPRX 1.19
  • GFS 1.56
  • MACD
  • RPRX 0.05
  • GFS -0.26
  • Stochastic Oscillator
  • RPRX 66.81
  • GFS 17.17

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

About GFS GlobalFoundries Inc.

GlobalFoundries is a top-five contract semiconductor manufacturer globally. It was originally the manufacturing arm of Advanced Micro Devices before it was spun out in 2009. The foundry sells chips into a range of end markets including smartphones, PCs, Internet of Things, data centers, automotive, industrial, and so on, but primarily focuses on more mature process technologies. Until 2021, the firm was privately held by Mubadala Investment, the sovereign wealth fund of the United Arab Emirates, which remains its controlling shareholder today. GlobalFoundries merged with Chartered Semiconductor Manufacturing in 2009 and acquired IBM's chipmaking business in 2015. GF is headquartered in Malta, New York, and employs about 13,000 people.

Share on Social Networks: